Literature DB >> 1126133

Effects of inhaled prostaglandins E1, E2, and F2alpha on the airway resistance of healthy and asthmatic man.

A P Smith, M F Cuthbert, L S Dunlop.   

Abstract

1. Changes in specific airway conductance after the inhalation of aerosols of prostaglandins (PG) E1, E2, and F2alpha were investigated in healthy and asthmatic subjects. 2. Inhalation of 155 nmol (55 mug) of PGE1 or 156 nmol (55 mug) of PGF2 resulted in consistent minor bronchodilatation in healthy subjects, but in asthmatic patients airway conductance increased significantly, along with subjective improvement. Isoprenaline (988 nmol; 550 mug) inhalation resulted in a similar increase in conductance to that obtained after these two prostaglandins, whereas a control aerosol had no effect. In contrast to the isoprenaline aerosol, both PGE1 and PGF2 were highly irritant to inhale. It was concluded that this made them unsuitable for therapeutic use. 3. Prostaglandin F2alpha inhalation resulted in a dose-related bronchoconstriction in healthy and asthmatic subjects. Asthmatics were approximately 150 than were the healthy subjects but there was very wide and significant variantion in the sensitivity of the asthmatic subjects. In contrast the asthmatic subjects were only 8-5 times more sensitive to histamine than the healthy subjects with less variation in response of individual subjects. The reasons for the hyper-reactivity of asthmatic subjects to PGF2alpha is unknown and no correlation could be drawn between increased sensitivity and age, type of asthma, or treatment. 4. The effects of disodium cromoglycate, flufenamic acid, atropine methonitrate, PGF2 and isoprenaline on PGF2alpha-induced bronchoconstriction were investigated in healthy subjects. Prostaglandin E2 reversed PGF2alpha-induced bronchoconstriction, as did isoprenaline, but prior treatment with the other drugs had no effect in preventing bronchoconstriction.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1126133     DOI: 10.1042/cs0480421

Source DB:  PubMed          Journal:  Clin Sci Mol Med        ISSN: 0301-0538


  25 in total

1.  Letter: prostaglandins and asthma.

Authors:  A P Smith
Journal:  Br Med J       Date:  1975-06-14

2.  Prostaglandins and asthma.

Authors:  M F Cuthbert
Journal:  Br J Clin Pharmacol       Date:  1975-08       Impact factor: 4.335

3.  Cough: physiology, evaluation, and treatment.

Authors:  A S Banner
Journal:  Lung       Date:  1986       Impact factor: 2.584

4.  Recombinant human enkephalinase (neutral endopeptidase) prevents cough induced by tachykinins in awake guinea pigs.

Authors:  H Kohrogi; J A Nadel; B Malfroy; C Gorman; R Bridenbaugh; J S Patton; D B Borson
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

5.  Neutral endopeptidase inhibitors potentiate substance P- and capsaicin-induced cough in awake guinea pigs.

Authors:  H Kohrogi; P D Graf; K Sekizawa; D B Borson; J A Nadel
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

Review 6.  PAF antagonists. Their potential therapeutic role in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Drugs       Date:  1988-02       Impact factor: 9.546

7.  Studies on L-640,035: a novel antagonist of contractile prostanoids in the lung.

Authors:  R Carrier; E J Cragoe; D Ethier; A W Ford-Hutchinson; Y Girard; R A Hall; P Hamel; J Rokach; N N Share; C A Stone
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

8.  Toxicity of prolonged high dose inhaled PGE1 in ventilated neonatal pigs.

Authors:  Beena G Sood; Elizabeth J Dawe; Krishna Rao Maddipati; Monica Malian; Xinguang Chen; Robert Galli; Raja Rabah
Journal:  Pulm Pharmacol Ther       Date:  2008-02-06       Impact factor: 3.410

9.  Effect of propranolol on the airway response to prostaglandin E2 in normal man.

Authors:  R V Seth; V S Clarke; R A Lewis; A E Tattersfield
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

Review 10.  Protease-activated receptors and prostaglandins in inflammatory lung disease.

Authors:  Terence Peters; Peter J Henry
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.